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The incidence of cutaneous malignant melanoma (CMM) has been increasing at a steady rate in fair-skinned populations around
the world for decades. Scientists are not certain why CMM has been steadily increasing, but strong, intermittent UVB (290–
320nm)exposures,especiallysunburnepisodes,probablyinitiate,CMM,whileUVA(321–400nm)passingthroughglasswindows
in oﬃces and cars probably promotes it. The CMM incidence may be increasing at an exponential rate around the world, but it
deﬁnitely decreases with increasing latitude up to ∼50◦N where it reverses and increases with the increasing latitude. The inversion
intheincidenceofCMMmayoccurbecausethereismoreUVArelativetoUVBformostoftheyearathigherlatitudes.Ifwindows,
allowing UVA to enter our indoor-working environment and cars, are at least partly responsible for the increasing incidence of
CMM, then UV ﬁlters can be applied to reduce the rate of increase worldwide.
1.Introduction
The incidence of cutaneous malignant melanoma (CMM)
has been increasing at a steady rate in fair-skinned popu-
lations around the world for decades [1–12]. Scientists are
not certain why CMM has been steadily increasing over
the decades, but strong intermittent UVB (290–320nm)
exposures, especially sunburn episodes, evidently initiates
CMM [13]. The UVA (321–400nm) passing through glass
windows in oﬃces and cars has been proposed to promote
CMM [14]. In support of those possibilities exists the
paradoxbetweenindoorandoutdoorworker’sUVexposures
and their incidences of CMM. Although outdoor workers get
three to ten times the annual UV dose that indoor workers
get [15, 16], they have similar or lower incidences of CMM
[17]. Scientists think the increasing incidence of CMM is
linear based on surveillance epidemiology and end results
(SEER) data in the USA that only dates back to 1973 [12],
but it may actually be exponential in the USA and in some
other regions of the world.
To understand what factor(s) may be responsible for the
increasing incidence of CMM, one must know the temporal
incidence for as many decades as possible. Because whatever
the causative agent is, or agents are, it must have entered
or left our environment some time (∼10–30yrs) before the
increasing trend was ﬁrst documented back in 1935 [1].
Thus, one can analyze the CMM incidence data for fair-
skinned people around the world and plot it temporally by
each country in the northern and southern hemispheres and
by latitude. Further analysis of R2 values can determine if
the curves are linear or exponential. This paper will analyze
the CMM incidences of fair-skinned populations all over the
world, test if the increases are exponential or linear, and
show that the increasing incidence decreases with increasing
latitude until ∼50◦N, where it reverses and begins to increase
with increasing latitude in Northern Europe.
2.MaterialsandMethods
One can obtain CMM incidence’s throughout the decades
from 1935 to 2007 for Australia, New Zealand, USA (except
Connecticut 1935–1940 [1] and 1945 [2]a n dN e wY o rkS t a t e
1955 [2]), middle Europe, Canada, and Northern Europe
from the International Agency for Research on Cancer
(IARC) [3–11]. The CMM incidence data from IARC was2 Journal of Skin Cancer
Table 1: Averaged CMM age-adjusted incidences among whites per 100,000 people (world population) in each country of the northern and
southern hemispheres (plotted in Figure 1); data is from [3–11] except 1940 [1], 1945, and 1955 [2]f o rt h eU S A .
Latitude/place 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000
30◦S Australia 16.33 17.89 21.43 25.90 32.20 32.13
40◦S New Zealand 6.10 7.65 9.55 15.55 18.50 20.80 27.40 31.70 33.10
40◦N USA 1.00 1.48 2.24 2.67 3.73 4.56 7.23 9.95 10.85 12.75 14.67 17.74
49◦N Middle Europe 1.50 1.48 1.55 2.01 2.02 2.47 2.86 3.12 3.78
52◦N Canada 2.00 2.12 2.64 3.18 4.73 5.97 7.08 7.95 9.74
60◦N Northern Europe 1.80 2.24 3.28 4.18 5.09 5.99 7.68 9.20 10.29 11.33
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Figure 1: Temporal exponential increase in the incidence of CMM
by latitude worldwide. Note that only New Zealand (40◦S) and
Northern Europe (60◦N) have linear rates of increase.
averaged from the following states/provinces/territories to
g e tam e a nv a l u ef o re a c hc o u n trya ta v e ra g el a t i t u d e( Table 1
and Figure 1):
(1) Australia (∼30◦S; range 19.5–42.5◦S)—Queensland
(19.5◦S), Western (24◦S), South (32◦S), New South
Wales (33◦S), Capital Territory (35.5◦S), Victoria
(36.5◦S), and Tasmania (42.5◦S).
(2) New Zealand (∼40◦S).
(3) USA (∼40◦N; range 20–47◦N)—Hawaii (20◦N),
Los Angeles, California (34◦N), Atlanta, Georgia
(34◦N), New Mexico (34◦N), San Francisco, Cali-
fornia (38◦N), Utah (39◦N), Connecticut (41.5◦N),
Iowa (42◦N), Michigan (43.5◦N), New York State
(43◦N; excludes New York City), and Washington
State (47◦N).
(4) Middle Europe (∼49◦N; range 46–52◦N)—Switzer–
land (46◦N), Slovenia (46◦N), Romania (46◦N),
Hungary (47.5◦N), Slovakia (48.5◦N), France
(48.5◦N; Bas-Rhin), Germany (49.5◦N; Saarland), all
of Poland (51◦N), The Netherlands (52◦N), and all
of England (52◦N).
1
10
100
25 35 45 55 65
Latitude (N)
C
M
M
i
n
c
i
d
e
n
c
e
/
1
0
0
K
w
o
r
l
d
p
o
p
u
l
a
t
i
o
n
Figure 2: The incidence of CMM in the world’s white populations
for the year 2000 based on IARC data. The trend line indicates an
increasing exponential incidence with decreasing latitude; however,
a reversal appears to occur above ∼50◦N where the incidence
increases with increasing latitude. Both Northern Europe and New
Zealand, where there is ozone depletion, only have linear increases
in the incidence of CMM; whereas, everywhere else in the world the
increasing incidence is exponential. Note that in Northern Europe
only Iceland has an exponential increase in CMM.
(5) Canada (∼52◦N; range 45–65◦N)—Nova Scotia
(45◦N), New Brunswick (46.5◦N), Prince Edward’s
Island (46.5◦N), Ontario (51◦N), Newfoundland
(53◦N ) ,Q u e b e c( 5 3 ◦N), Alberta (54◦N), British
Columbia (54◦N), Manitoba (54◦N), Saskatchewan
(54◦N), and Northwest Territories (65◦N).
(6) Northern Europe (∼60◦N; range 53–65◦N)—Ireland
(53◦N), Denmark (56◦N), Scotland (57◦N), Sweden
(62◦N),Iceland (63◦N), Norway (64◦N), and Finland
(65◦N).
Figure 2 has the same CMM incidence data for the year
2000 as shown in Figure 1 only plotted by latitude [1–11].
Figures 3(a) and 3(b) show CMM incidence data from
[1–11], which includes 10 registries, the same 9 registries as
SEER 9 along with Los Angeles. Figure 4(a) CMM incidence
data for the USA (1973–2007) is from the SEER website
at (http://seer.cancer.gov/faststats/selections.php/)[ 12]. The
data type is “SEER incidence,” the statistic type is “age-
adjusted,” the year range is 1975–2007 (SEER 9), and the
race/ethnicity is “white (includes Hispanics),” for both sexes
of all ages. SEER 9 (white includes Hispanic) compared
to SEER 17 (non-Hispanic white) has ∼1-2/100,000 people
lower incidence of CMM. The SEER 9 registries are Atlanta,
Georgia; Connecticut; Detroit, Michigan; Hawaii; Iowa;Journal of Skin Cancer 3
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Figure 3: (a) The data indicates an increasing incidence of CMM in the white population of the USA for six decades at three latitudes:
∼34◦N (average of Los Angeles, California; Atlanta, Georgia; New Mexico), 39◦N (average of San Francisco, California, and Utah) and 43◦N
(average of Iowa, Michigan, Connecticut, and Upstate New York). The CMM incidences at 34◦Na n d4 3 ◦N are increasing at exponential
rates while at 39◦N, it is increasing at a linear rate (determined by comparing R2 values for the linear and exponential trend lines). (b) The
CMM incidence data at 39◦N changes from linear to exponential and the 43◦N data changes from exponential to linear when Connecticut is
averaged with San Francisco and Utah.
New Mexico; San Francisco-Oakland, California; Seattle-
Puget Sound, Washington; Utah. Data are available for
cases diagnosed from 1973 and later for these registries
with the exception of Seattle-Puget Sound and Atlanta. The
Seattle-Puget Sound and Atlanta registries joined the SEER
program in 1974 and 1975, respectively. Seer 11 includes Los
Angeles and San Jose-Monterey, California starting in 1992.
Figure 4(b) shows the same data [12]a si nFigure 4(a) only
extended back to 1940 using data from [1–11].
3. Results
Table 1 contains the averaged CMM incidences of fair-
skinned populations around the world from 1940 to 2000
for each country or region of the world [1–11]: Australia
(∼30◦S), New Zealand (∼40◦S), USA (∼40◦N), Middle
Europe (∼49◦N), Canada (∼52◦N), and Northern Europe
(∼60◦N). New Zealand has the highest incidence of CMM
closely followed by Australia while Middle Europe has the
lowest incidence.
Figure 1 shows a temporal plot of the CMM incidence
from 1940 to 2000 [1–11]. Note that Australia, USA, Middle
Europe, and Canada all have exponential increases except
New Zealand and Northern Europe, which have linear
increases. In fact, all the countries of Northern Europe
have linear increases in CMM except Iceland, which is
exponential.
Figure 2 shows the incidence of CMM in 2000 decreases
with increasing latitude up to ∼50◦N where it changes
and begins to increase with increasing latitude in Northern
Europe [1–11]. Notice that the CMM incidence increases
with decreasing latitude; however, near 50◦N in Northern
Europe the incidence begins to increase with increasing
latitude. Note that the CMM incidence data from 1960 to
2000 all show the same change near 50◦N (see Table 1).
Figure 3 shows the CMM incidence data in the USA
analyzed in diﬀerent ways to know whether or not the
increase is exponential or linear [1–11]. Figure 3(a) shows
how the CMM incidence data at 39◦N can be linear if we
only average San Francisco and Utah together. The data
at 43◦N is exponential because Connecticut is included in
that data set. Figure 3(b) shows that when the Connecticut
CMM incidence data is included with the 39◦N data, it
becomes exponential, while the data at 43◦N becomes linear.
Connecticut data extends a couple of decades further back
in time (to 1935), which may be necessary to know if the
trend is truly linear or exponential but might represent
underestimates in CMM during that earlier time frame that
would make the data appear to be exponential when it is
really linear.
Figure 4(a) shows the SEER 9 data from 1975 to 2005
[12], which appears to be almost perfectly linear (R2 is
0.9954), possibly because it does not extend far enough into
the past as the data presented in Figures 1, 3(a),a n d3(b).
Figure 4(b) shows the same SEER 9 data [12]i nFigure 4(a)
only extended back in time to 1940 using references [1]
through [11]. This changes the USA data from a linear (R2
is now 0.9189) to an exponential (R2 is 0.9755) increase in
the incidence of CMM.
4. Discussion
The incidences of CMM in fair-skinned, indoor-working
people have been increasing worldwide for decades
(Figure 1). The countries with the highest incidences per
annual erythemally weighted UV dose [15]a r ec l o s e s tt o4 Journal of Skin Cancer
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Figure 4: (a) The SEER 9 data from 1975 to 2007 indicates a linear increasing incidence in CMM (R2 is 0.9954). Five years of data was
averaged to obtain each data point, for example, the data point for 1975 includes averaged data from 1973 to 1977. If the data is plotted out
year by year the trend line and R2 values indicate it is a linear increase since 1973. Even if we add the IARC data for 1960, 1965, and 1970 to
the SEER data, the incidence is still increasing in a linear manner from 1960 to 2005. (b) However, if one adds in the data for Connecticut
and New York State extending it back 6 decades to 1940, then the increase appears to be exponential (R2 is 0.9755) rather than linear (R2 is
now 0.9189).
the equator: Australia (∼30◦S), New Zealand (∼40◦S), and
the USA (∼40◦N). The regions of the world with lowest
fair-skinned incidences of CMM are in Middle Europe,
around 49◦N; however, the decreasing trend with increasing
latitude changes around ∼50◦N so that Canada (∼52◦N)
and Northern Europe (∼60◦N) have higher incidences
than Middle Europe (Figure 2). In fact, Northern Europe
at ∼60◦N has a higher incidence than Canada at 52◦Na n d
almost equates the incidence in the USA at ∼40◦N. The
increasing incidence of CMM appears to be exponential in
most regions except Europe; however, as analysis in Figures
3(a) and 3(b) show, data in the USA extending to 1940
can make the CMM incidence appear to be exponential.
The SEER data from 1973 to 2007 suggests that the CMM
incidence is linearly increasing in the USA (R2 is 0.9954,
Figure 4(a)). However, when the Connecticut [1, 2], New
York State [2], and IARC data [3–11] extend the SEER
data back to 1940, the incidence of CMM in the USA
increases in an exponential manner (Figure 4(b)), possibly
indicating that longer periods are needed to know if the
increase is truly linear or if it is really exponential. Thus,
we cannot be completely certain if the increase is linear
or exponential in other countries because it may be that
the data has to be collected for ﬁve decades or more to be
conclusive.
Whether or not the incidence of CMM is increasing
linearly or exponentially does not change the fact that it is
increasing at the alarming rate of about 4-5% per year. In
order to slow or stop this increasing trend, one must know
what is causing it and change it. Based on the temporal plot
shown in Figure 1, we know whatever started the increasing
incidence of CMM either entered or left our environment
before 1935, because that is when we have documented data
for the ﬁrst increases in CMM in the USA. Fluorescent
lights (mid-1940’s; [18]), sunscreens (late 1950’s for UVB
absorbing and 1988 for UVA and UVB absorbing; [19]), and
tanning devices (∼1978; [20]) all entered our environment
after the increasing incidence of CMM was ﬁrst documented
in the USA back in 1935 [1]. Thus, one should analyze what
happened before 1935—during the early 20th century—to
discover what may have really aﬀected the incidence of
CMM.
In the early 20th century, people went against evolution
by going indoors during the day to work, which drastically
decreased their daily amount of cutaneous vitamin D3 and
exposed them to only UVA radiation passing through glass
windows [14]. The artiﬁcial UV barrier created by windows
divided UVB from UVA, so that the vitamin-D-making UVB
wavelengths [21] were excluded and only the vitamin-D-
breaking [22] and DNA-mutating UVA wavelengths [23–25]
were included in our indoor-working environment. Possibly
because this unnatural UV environment existed for decades
in buildings and later in cars [26], CMM was promoted by
UVA, after being initiated by UVB sunburns and began to
steadily increase in the mid-1930’s.
Along these lines of reasoning, we now also have the
increasing incidence of CMM with increasing latitude above
∼50◦N( Figure 2). People living above 50◦N go to the beach
during the summer and get sunburned at lower latitudes to
initiate CMM and then return home to northern latitudes
that have primarily UVA for most of the year to promote
CMM. The higher latitudes also allow the sun to aim more
often at a perpendicular angle to the window glass allowing
more UVA to pass through and directly expose people’s skin
duringtheirworkday.Inaddition, above ∼50◦Nthereislittle
UVB to make cutaneous vitamin D3 most of the year [27].
Further, in the northern regions of the world (above 37◦N),
a vitamin D3 “ w i n t e r ”o c c u r sf r o ma tl e a s tN o v e m b e rt o
February, which extends from October to March at higher
latitudes, when the dose rate of UVB is too low to make any
previtamin D3 even if an oﬃce worker goes outside during
peak hours [27]. On the other hand, UVB exposure during
peak hours occurs to outdoor workers to some extent during
their workweek, so that they can maintain adequate levels of
vitamin D3 in their skin and blood (as 25-hydroxyvitamin
D) for most of the year. Note that the blood levels of vitaminJournal of Skin Cancer 5
D (measured as 25-hydroxyvitamin D in serum) in outdoor
workers (gardeners), who get about ﬁve times the solar
dose that indoor workers get, are about twice as high as
indoor workers [28]. The reason vitamin D is important
for controlling melanoma is because it can be converted to
the hormone calcitriol inside melanoma cells [29]. Calcitriol
can control the growth [30–32]a n da p o p t o t i cc e l ld e a t h
[33] of responsive melanoma cells, while it also aﬀects the
immune system [34, 35] and inhibits tumor promotion [36],
which may all be responsible for increasing the survival of
melanoma patients who get regular, moderate sun exposures
[37]. Thus, intermittent, strong UVB-induced sunburns may
initiate CMM, while low concentrations of vitamin D3 [38]
in the skin and UVA-induced DNA damage may promote
CMM [14].
5. Conclusions
The incidence of CMM is increasing at an alarming rate
around the world in fair-skinned, indoor-working pop-
ulations, and may be increasing at an exponential rate.
The CMM incidence decreases with increasing latitude up
to ∼50◦N where it changes and increases with increasing
latitude. This inverse may occur because there is more UVA
relative to UVB for most of the year at higher latitudes
compared to lower latitudes. If windows, allowing UVA to
enter our indoor-working environment and cars, are at least
partly responsible for the increasing incidence of CMM,
then UV ﬁlters can be applied to oﬃce and car windows to
help reduce the rate of increase in the incidence of CMM
worldwide.
Abbreviations
CMM: Cutaneous malignant melanoma
IARC: International Agency for Research on Cancer
SEER: Surveillance epidemiology and end results
USA: United States of America
UVA: 321–400nm
UVB: 290–320nm.
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